Literature DB >> 11357932

Cardiac arrhythmias: the possible role of the renin-angiotensin system.

W C De Mello1.   

Abstract

Activation of the renin-angiotensin system during the process of heart failure may predispose the heart to reentrant malignant arrhythmias by reducing the cell coupling and conduction velocity. Here I discuss the possible role of the renin-angiotensin system on the modulation of cell coupling and impulse propagation with consequent generation of reentrant rhythms. Particular emphasis is given to the effects of angiotensin II on the electrical properties of the failing heart and the beneficial effects of angiotensin-converting enzyme inhibitors and angiotensin II AT1 receptor blockade.

Entities:  

Mesh:

Year:  2001        PMID: 11357932     DOI: 10.1007/s001090100195

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  5 in total

Review 1.  Clinical implications of local renin-angiotensin-aldosterone systems.

Authors:  Edward D Frohlich
Journal:  Curr Cardiol Rep       Date:  2003-07       Impact factor: 2.931

2.  Intracrine action of angiotensin II in the intact ventricle of the failing heart: angiotensin II changes cardiac excitability from within.

Authors:  Walmor C De Mello
Journal:  Mol Cell Biochem       Date:  2011-07-09       Impact factor: 3.396

3.  Intracellular angiotensin-(1-12) changes the electrical properties of intact cardiac muscle.

Authors:  W C De Mello; L J Dell'Itallia; J Varagic; C M Ferrario
Journal:  Mol Cell Biochem       Date:  2016-09-02       Impact factor: 3.396

4.  Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.

Authors:  Y H Wang; C X Shi; F Dong; J W Sheng; Y F Xu
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 5.  Clinical perspectives and fundamental aspects of local cardiovascular and renal Renin-Angiotensin systems.

Authors:  Walmor C De Mello; Edward D Frohlich
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-19       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.